NCT00100828终止2 期
Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2004年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 2
- 主要终点
- Response Rate
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with metastatic or inoperable thyroid cancer.
详细描述
OBJECTIVES:
Primary
- Determine the response rate in patients with metastatic or inoperable locoregional medullary thyroid cancer treated with irinotecan.
Secondary
- Determine the safety and tolerability of this drug in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Irinotecan
Experimental
干预措施: irinotecan hydrochloride (Drug)
结局指标
主要结局
Response Rate
时间窗: Every 2 cycles
To determine the response rate of this regimen of irinotecan in patients with metastatic MTC
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Irinotecan and Cetuximab in Treating Patients With Metastatic Breast CancerBreast CancerNCT00275041Alliance for Clinical Trials in Oncology21
已完成
1 期
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid TumorsBrain and Central Nervous System TumorsCognitive/Functional EffectsLong-term Effects Secondary to Cancer Therapy in AdultsLong-term Effects Secondary to Cancer Therapy in ChildrenPoor Performance StatusUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol SpecificNCT00389584University of California, Davis30
终止
2 期
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and BevacizumabColorectal CancerNCT00588900Alliance for Clinical Trials in Oncology5
已完成
2 期
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaLymphomaNCT00003245M.D. Anderson Cancer Center50
已完成
2 期
Irinotecan in Treating Patients With Newly Diagnosed Ewing's SarcomaSarcomaNCT00276692Children's Cancer and Leukaemia Group35